Despite this, Atacicept (TACI-Ig), a therapeutic that blocks BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand) signaling and drives the depletion of B lineage subsets, worsens MS disease and optic neuritis, and increases relapse rate (134, 135). This evidence concerns the gene TNFSF13 and optic neuritis.